Go Pro
NASDAQ:IMCC

IM Cannabis Q2 2025 Earnings Report

IM Cannabis logo
$3.09 -1.14 (-26.95%)
As of 04:00 PM Eastern

IM Cannabis EPS Results

Actual EPS
-$1.96
Consensus EPS
-$4.10
Beat/Miss
Beat by +$2.14
One Year Ago EPS
N/A

IM Cannabis Revenue Results

Actual Revenue
$9.21 million
Expected Revenue
$12.88 million
Beat/Miss
Missed by -$3.67 million
YoY Revenue Growth
N/A

IM Cannabis Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
9:00AM ET

Upcoming Earnings

IM Cannabis' Q3 2026 earnings is estimated for Monday, November 16, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

IM Cannabis Earnings Headlines

Critical Analysis: Indivior (OTCMKTS:INVVY) & IM Cannabis (NASDAQ:IMCC)
Penny Stocks To Follow Now - September 18th
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel
Top Cannabis Stocks To Watch Now - September 18th
Cannabis Stocks To Watch Now - September 19th
Penny Stocks To Consider - September 19th
See More IM Cannabis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IM Cannabis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IM Cannabis and other key companies, straight to your email.

About IM Cannabis

IM Cannabis (NASDAQ:IMCC) is a medical cannabis company that operates primarily in Israel and Germany. The company develops, imports, distributes and sells medical cannabis products through the IMC brand and related product lines.

Its product portfolio includes medical cannabis flower, oils and other cannabis-based products. In Israel, IM Cannabis serves the regulated medical cannabis market through activities that include product sourcing, distribution and sales to authorized patients and pharmacies. In Germany, the company participates in the medical cannabis supply chain, including the wholesale distribution of pharmaceutical-grade cannabis products.

IM Cannabis was established as an international medical cannabis operator and became publicly traded in North America in 2021. The company previously had Canadian operations but has since focused its business on its core markets in Israel and Germany. Oren Shuster has served as the company’s chief executive officer.

View IM Cannabis Profile